PiMMs
Research type
Research Study
Full title
A Retrospective, Multi-Centre, Observational Study of Outcomes and Toxicity of Panobinostat in combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma in a UK real world setting (PiMMS)
IRAS ID
276830
Contact name
Reuben Benjamin
Contact email
Sponsor organisation
Kings College Hospital R&I Office
Clinicaltrials.gov Identifier
NA, NA
Duration of Study in the UK
1 years, 0 months, 1 days
Research summary
This study will investigate the real-world outcomes for patients receiving Panobinostat for myeloma at hospitals in England.
The primary objective is the evaluation of progression-free survival (PFS) of relapsed/refractory multiple myeloma (RRMM) patients receiving panobinostat in combination with bortezomib and dexamethasone following at least 2 prior regimens including bortezomib and an immunomodulatory agent. The study will also investigate other measures of response depth and length, toxicity and tolerability as measured by incidence and severity of adverse events and dose modifications in real world practice, and health economics measures, determined by number of outpatient, inpatient, and intensive care admissions and length of inpatient stay while on active treatment with Panobinostat.
The study will comprise the retrospective collection of existing routine clinical data, with no additional input required from patients.
REC name
West Midlands - Black Country Research Ethics Committee
REC reference
20/WM/0213
Date of REC Opinion
23 Jul 2020
REC opinion
Favourable Opinion